Pharmaceutical market regulatory authorities, expecting remote inspections to continue with an important role even after COVID-19 pandemic-related travel restrictions have ended, have launched efforts to develop a globally acceptable approach to how these should be undertaken.
Global Pharma Industry Regulators Seek Unified Approach To Remote Inspections
Remote inspections are here to stay, and global regulators are aligning efforts to develop consensus on how these should be conducted.
More from Manufacturing
• By
With the acquisition of HKS Health Solutions, 1Q Health Group states its ambition to be the leading full-service CDMO in Europe. Separately, Italy's Ourvita enhances its capabilities through a deal for Poland's Laboratoria Natury.
• By
Testing by third-party lab accumulated 35,862 data points from 70 brands and 160 products as a benchmark for the study’s findings. Council for Responsible Nutrition criticized the study as lacking “critical context” and potentially “misleading consumers rather than empowering them.”
• By
Petition by Leprino Nutrition could help manufacturers trim production spending as costs increase throughout the supply chain leading to higher product prices even as the global whey protein ingredient market reached nearly $9bn in 2023 and is projected to reach nearly $23bn in 2032.
• By
CRN suggestion that FDA prioritize facility inspections on firms which haven’t been cleared in third-party audits apparently has support at agency. But FDA hasn’t been receptive to adjusting its policy on precluding from use as dietary ingredients any substance studied or approved as a drug.
More from Business
• By
Chinese consumers are now routinely taking supplements for a variety of health reasons, helping to drive up sales of the Swisse Plus+ brand by 20% in 2024.
• By
Growing use of GLP-1 receptor agonists is having a positive knock-on effect on the dietary supplements market, reports OptiBiotix Health, marketer of the SlimBiome weight management prebiotic.
• By
By taking a majority stake in dynamic dietary supplements firm Braineffect, Germany's Schwabe can reach a new, younger target audience for its OTC herbal medicines.